Bauer et al., 2021 [293], demonstrated that the methylation status of peripheral blood mononuclear cells (PBMCs) could predict the LVEF reduction after treatment with DOX in HER2-negative breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.